Tributary Capital Management LLC and
SG Americas Securities LLC have both increased their positions in
PTC Inc.. The company's stock has been outperforming the Dow, and despite some market weakness, its strong financial prospects suggest potential undervaluation.
PTC Therapeutics saw soaring stock prices following a licensing agreement with Novartis. Compared to other design software stocks, PTC's Q3 earnings held strong and it is projected to post earnings again on Wednesday. Several institutional investors, such as
Advisory Alpha LLC and
Diversify Wealth Management LLC, have also increased their positions in PTC Inc. However,
Exchange Traded Concepts LLC sold 13,095 shares and
Wealth Enhancement Advisory Services LLC reduced their holdings. Despite this, those who invested in PTC five years ago have seen a 145% increase. PTC's Q4 earnings surpassed estimates, reflecting a rise in revenues. The company also recently unveiled a $2B Share Buyback Plan and aims to reach a $300M Target for 2025. Although there have also been instances of insider selling such as by
Matthew Klein, CEO of PTC Therapeutics, the overall business outlook for PTC appears optimistic.
PTC Stocks News Analytics from Mon, 20 May 2024 07:00:00 GMT to Sat, 25 Jan 2025 14:00:31 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -5
